Verastem Oncology reported new data across multiple tumor types for its KRAS-mutant program VS-7375 and simultaneously announced a leadership change and funding. The company said its experimental drug showed early promise in a small study, supporting a plan to launch three late-stage trials before the end of June. Verastem also revealed a $250 million raise and that its CEO would depart, with a new President and CEO Michael Bailey scheduled to take over effective Jan. 1, 2027. The combination of clinical updates and financing underscores Verastem’s intent to maintain momentum in the increasingly crowded KRAS landscape. For biotech watchers, the key near-term signals are whether VS-7375 can show durable activity by KRAS allele—particularly against G12D—and how the company scales clinical development with the new capital.